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Summary: Results of therapeutic trials with physostigmine in the treatment of 
Alzheimer disease (AD) have been inconsistent and controversy persists con-
cerning safety and efficacy. In a double-blind, placebo-controlled, crossover 
study, patients received 6 weeks of oral physostigmine (OP) and placebo in 
random order. Twenty-nine patients with AD received as much as 16 mg/day 
of OP and were assessed with neuropsychological and functional measures. No 
significant cardiac side effects were noted, though other systemic adverse 
effects were noted, requiring dose reduction in four patients. There was a slight 
but significant improvement (12%) in performance on the selective reminding 
test with physostigmine and the memory performance was correlated with 
dosage. This improvement compares favorably with the 15% decrease in 
scores seen in an untreated comparison cohort followed for an equivalent time 
period. There was a trend toward an improvement in communication and a 
reduction in memory complaint. These results suggest that oral physostigmine 
is safe and may improve memory in AD. Key Words: Alzheimer disease-
Physostigmine-Safety-Efficacy. 
Oral physostigmine (OP), a cholinesterase inhibitor, has frequently been used 
as an experimental treatment for memory and cognitive loss in probable Alzhei-
mer disease (AD). The results of these studies have been inconsistent, due in part 
to methodological differences. Initially, investigators used short dose-finding pe-
riods to determine the most effective dose based on memory performance (1,2). 
This dose-finding procedure may have maximized side effects at low doses while 
longer treatment may allow tolerance to develop (3). Furthermore, short-term 
exposure was not useful in predicting the improvement found in a longer study 
(4-6). 
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To determine the efficacy of physostigmine in patients without prior exposure 
to the drug, we conducted a trial in patients with AD using a double-blind, pla-
cebo-controlled, crossover design. A dose-titration period was used to maximize 
exposure to drug and testing procedures but was not used to determine an effec-
tive dose. Cognitive and functional assessments at a maximum dose of 16 mg/day 
were made after a period of 6 weeks. Cardiac and systemic side effects were 
monitored to assess safety. 
METHODS 
Subjects 
Twenty-nine patients who met NINCDS-ADRDA research diagnostic criteria 
for probable or possible AD (7) gave informed consent to participate in the study. 
Subjects were living at home with varying degrees of supervision throughout the 
study period. Each had an identified caregiver (usually a spouse or child) who 
acted as an advocate for the patient in the matter of informed consent. 
Procedures 
The patients were initially admitted to the General Clinical Research Center 
(GCRC) at Columbia Presbyterian Medical Center. On the day of admission, the 
Selective Reminding Test (SRT) was administered as a baseline measure. 
Phase One: Titration 
This phase lasted 2 days . Patients received five different doses of OP, ranging 
from 2 to 4 mg in 0.5 mg increments. Each day began with a dose of 2 mg. This 
was followed by four other doses at 2 h intervals, administered in random order. 
The SRT was administered six times during this period using a different equivalent 
form each time. This procedure was designed to familiarize the subject with test 
taking. The highest dose tolerated without serious side effect was chosen for each 
patient. 
Phase Two: Double Blind 
Double-blind random assignment was used to determine the order of drug and 
placebo assignment (i.e., drug followed by placebo or placebo followed by drug). 
Drug and placebo were administered for 6 weeks. Drug A (OP or placebo) was 
administered at 2 h intervals, four times a day at the dose chosen in phase 1. 
Patients were discharged if they were free of side effects after receiving the initial 
two doses. They continued to take the medication under supervision at home for 
6 weeks. At the end of the 6 week interval, patients returned to the GCRC and 
underwent memory testing 30 min after drug administration. This was done twice 
(after the 0900 and 1300 h doses) and the average of the two scores was recorded. 
Routine serum chemistries were drawn. An electrocardiogram (ECG) and other 
outcome measures (described below) were also completed at this time. 
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Phase Three: Double-Blind Crossover 
On the day following the end of phase two, the patients received the first two 
doses of the alternate medication and were discharged if they were symptom free. 
They continued medication according to the same schedule used in phase two. 
Patients returned to the GCRC and assessment procedures identical to those in 
phase two were repeated. 
Medication 
Physostigmine (physostigmine salicylate), supplied in 1 mg tablets, and identi-
cal placebo was provided by the Forest Pharmaceuticals Inc., a subsidiary of 
Forest Laboratories Inc. (St. Louis, MO, U.S.A.). 
Outcome Measures 
Primary Outcome Measure 
For comparability with other studies (1,2,4,5), the primary outcome measure 
was performance on the SRT. In this 12 item, 12 trial, verbal memory test, mod-
ified from Buschke and Fuld (8), three measures are derived: Total Recall (the 
total number of words recalled), Long Term Retrieval (the number of words 
recalled without reminding), and Intrusions, words recalled that are not on the list 
(each occurrence after a single correction). Incidental recall is assessed 15 min 
later. A recognition trial follows, in which the subject discriminates words on the 
list from distractor words. Different, equivalent forms of this test were used at 
each administration. Additional details of the administration and scoring proce-
dure were previously described (1,4). 
Other Outcome Measures 
Independent function was assessed with two instruments that were completed 
by the caregiver: The Sickness Impact Profile (SIP) (9), a standardized question-
naire that measures the impact of illness on functional abilities in the areas of 
Sleep and Rest, Home Management, Recreation and Pastimes, Physical Activities 
(including ambulation, mobility, body care, and movement), and Psychosocial 
Activities (including social interaction, alertness behavior, emotional behavior, 
and communication), yields a total score and subscale scores for each area. The 
Squire's Memory Questionnaire (SMQ) (10) measures memory in daily activities. 
Cardiac and Side Effect Evaluation 
Patients received baseline ECGs prior to receiving physostigmine in the titra-
tion phase. At the end of each 6 week interval, an ECG was performed 30 min 
after administration of medication. Systemic side effects (such as nausea, vomit-
ing, and diaphoresis) were also recorded for each phase based on a review of 
nursing notes and interviews with the patient and/or caregiver. 
Clin. Neuropharmacol., Vol. 16, No . 1, 1993 
64 M. SANO ET AL. 
Data Analysis 
The effect of OP on the SRT was assessed using paired t tests. A two-way 
analysis of variance was used to examine treatment and order effects. Drug and 
placebo performance differences were also examined for the neuropsychological 
and independent function measures using paired t tests. In addition, correlations 
between dose, demographics, and outcome measures were examined. 
RESULTS 
Description of Subjects 
The mean age ± SD of the patients was 69 .1 ± 9 .1 years with an average 
duration of illness of 4.2 ± 0.3 years. The mean score on the Modified Mini-
Mental State Examination (mMMSE) was 35.65 ± 7.22. This is equivalent to an 
18 on the of Mini-Mental State Examination (MMSE) described by Folstein et al. 
(11,12). 
Primary Outcome Measures 
The mean values for the SRT scores for the drug and placebo conditions are 
given in Table 1. There was a significant difference between the drug and placebo 
condition in the Total Recall (p < 0.01) and the Intrusion scores (p < 0.01). There 
were no significant differences in the other SRT scores. 
Table 2 presents the results of a two-way analysis of variance for the Total 
Recall and Intrusion scores to examine the effect of treatment (drug vs. placebo) 
and order (drug first vs. placebo first). There was a significant main effect for drug 
(F = 5.30, p < 0.05). The effect of order and the interaction of drug and order 
were not significant. 
The average total daily dosage was 13.11 ± 2.31 mg. There was a small but 
significant correlation between dose and change in the SRT Total score (r = 0.48; 
p < 0.05). Change in SRT Total score did not correlate with mMMSE score at 
baseline, age, or duration of illness. 
Other Outcome Measures 
There was no significant change between the drug and placebo conditions for 
the SIP total score. The communications subscale demonstrated a significant 
TABLE 1. Performance on the Selective Reminding Test (SRT) (mean ± SD) in patients 
with Alzheimer disease 
SRT measures 
Total Recall 





57.1 ± 20.9 
29.6 ± 18.9 
5.4 ± 5.8 
1.0 ± 1.7 
7.7 ± 2.8 
Placebo 
52.9 ± 21.1 
26.8 ± 17.9 
8.5 ± 8.6 
1.2 ± 1.9 
7.5 ± 2.8 
* Significant difference between drug and placebo, p < O.Ql . 
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Physostigmine/placebo 
difference 
4.2 ± 7.7* 
2.8 ± 9.8 
-3.0 ± 6.5* 
-0.2 ± 2.2 
0.2 ± 1.7 
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TABLE 2. Two-way analysis of variance of the total recall and intrusion score from the 
selective reminding test to examine the effect of order and treatment (physostigmine 
vs. placebo) 
df 
Total recall score 





































improvement (p < 0.01) for the drug condition. No other subscale changed sig-
nificantly. 
The improvement for drug condition in the overall SMQ score reached border-
line significance (p < 0.06); there were no differences in the individual items on 
this scale. 
Cardiac and Systemic Side Effects 
Eight patients had ECG abnormalities at baseline: one had left bundle branch 
block, one had left anterior fascicular block, one had left inferior wall infarct, one 
had atrial fibrillation, one had first-degree atrioventricular block, one had left 
atrial enlargement, one had premature supraventricular complexes, and one had 
nonspecific T-wave abnormalities. 
Eight patients had sinus bradycardia (three had borderline values of 59 beats/ 
min). Five patients had sinus bradycardia in both drug and placebo conditions. 
Three patients had sinus bradycardia in the drug condition only and one in the 
placebo condition only. There was no association between dosage and heart rate 
or the presence of any other cardiac abnormality. 
The frequency of systemic side effects is described in Table 3. Fifteen (52%) 
patients experienced systemic side effects during the titration phase of the study. 
TABLE 3. Frequency of reported systemic side effects in each phase of the study 
Symptom Titration phase Active drug Placebo 
Nausea 12 2 2 
Vomiting 6 0 1 
Diaphoresis 2 0 0 
Diarrhea 1 1 1 
Dizziness 0 1 1 
Headache 0 0 I 
Total number with any side effect 15 4 4 
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Twelve of the patients experienced nausea and 6 vomited. Other systemic side 
effects were dizziness, diaphoresis, and diarrhea. Four patients had their medi-
cation dosage decreased in the initial few weeks of the double-blind phase because 
of side effects. 
Despite dosage adjustments in the titration period, five patients experienced 
intermittent adverse symptoms in the double-blind phases. Two patients had nau-
sea and diarrhea and one had dizziness on both drug and placebo. One patient had 
intermittent headaches only on OP and one had nausea and vomiting only on 
placebo. 
There were no clinically significant changes in blood counts, liver enzymes, or 
other chemistry results. Chloride levels were increased in six patients: two on 
drug only and four on drug and placebo. Alkaline phosphatase levels were ele-
vated in two patients: one on drug only and one on both drug and placebo. These 
elevations were not considered clinically significant. 
Post Hoc Analyses to Evaluate the Effect on SRT 
To evaluate the effect seen on the SRT, retrospective comparisons were made 
with a cohort of patients with AD, described elsewhere (13), receiving placebo for 
a period of 6 months. For this comparison, the interim SRT scores (3 months, i.e., 
12 weeks) were examined since that was the time interval of the entire crossover 
period. These patients received a six-trial version of the SRT; thus, all scores 
were converted to percent of baseline to make comparisons. In the current study, 
28 of the 29 patients had baseline SRT scores. The SRT Total Score increased 12% 
over baseline during the OP phase compared to a 1% increase on placebo. The 
size of the change varied with the order in which drug and placebo were admin-
istered but significantly better performance was observed with drug than with 
placebo. In the previously described cohort (13), the SRT Total Score demon-
strated a 15% decrease from baseline during a 3 month interval. The change scores 
for both groups are illustrated in Fig. 1. 
DISCUSSION 
The use of physostigmine for improving memory and cognition in patients with 
AD has been frequently studied and there is a small but significant improvement 
in formal memory testing (1-5, 14). These studies lend support to cholinesterase 
inhibition as a mechanism for treatment of memory loss in AD. The present study 
also demonstrates statistically significant improvement in memory testing with OP 
in patients with AD. Overall, the group demonstrated a 12% improvement over 
baseline in memory scores. While the exact clinical meaningfulness of this change 
is difficult to assess, it is known that memory performance deteriorates with 
disease progression in AD. For example, a previous study found that SRT Total 
Recall score decreased 15% in 3 months and 21 % in 6 months (13). The retro-
spective nature of the comparison limits the conclusions that can be drawn. How-
ever, the improvement seen with OP may be meaningful. 
There was little change in the functional scales used in this study. The improve-
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% Change in SRT Taal Score 
Weeks from Baseline 




Weeks from Baseline 
P=Placebo; D=Physostigmine. 
Order A= drug phase first; Order B=placebo phase first. 
Comparison cohort tested at 12 weeks only. 
67 
12 
FIG. 1. Selective reminding test: total score. Change from baseline in SRT total score in patients with 
Alzheimer disease with physostigmine treatment and in a comparison cohort. Bar graph describes 
effect of physostigmine; line graph describes a placebo-treated comparison cohort. 
ment in the communication subscales of the SIP and a trend toward an improve-
ment in the SMQ, a subjective measure of memory complaint, must be viewed 
with caution given the multiple comparisons that were conducted on these mea-
sures. These findings suggest other domains that might be assessed in clinical 
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trials to determine if statistical improvement in memory test scores reflect a 
clinically meaningful effect. 
There was a significant relationship between improvement on memory testing 
and dose of OP. This relationship has not been demonstrated before, although 
previous studies have used lower doses, perhaps because of concerns about car-
diac side effects. Intravenous administration of physostigmine for confusion, dis-
orientation, and coma following anesthesia has been associated with sinus bra-
dycardia (due to increased vagal tone at the sinoatrial node), atrial fibrillation (15), 
ventricular tachycardia, and premature ventricular contractions (16). In the pre-
sent study, ECG findings suggests that at these doses there was no significant 
change in cardiac status, even in patients with baseline abnormalities. Systemic 
side effects such as nausea and vomiting are well known with OP (3) and though 
these are thought to be a Jess serious threat, they represented the limiting factor 
in this study. The dose was reduced at the first report of side effect. No attempt 
was made to reinitiate a higher dose or to treat the side effect. This strategy 
limited the size of doses, which might have also limited efficacy. Given the rela-
tive safety demonstrated in this study, further investigation at higher doses should 
be considered. 
The limited improvements may also be due to the specific agent, physostigmine. 
Amal et al. have described a centrally active cholinesterase inhibitor (an analogue 
of pyridostigmine, norpyridostigmine) that is effective at doses that have less side 
effects than physostigmine in animal models (17). Behavioral studies in animals 
have demonstrated that norpyridostigmine improves accuracy in a maze learning 
task in a dose-related fashion (18). In addition, other cholinesterase inhibitors with 
longer duration of action have been examined in animal models . Perhaps other 
cholinesterase inhibitors, with central nervous system specificity and minimal 
peripheral activation, would prove to be useful agents. 
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